Quotient and Bend discuss new collaboration at AAPS

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Quotient Clinical and Bend Research have teamed up to tackle solubility issues in early clinical development.

Outsourcing-pharma spoke with Quotient Clinical managing director Mark Egerton and Bend Research CEO Rod Ray, who predicted that combining the former’s trial design capabilities with the latter’s formulation technology, will offer customers a faster way to bring candidates to trial.

"Poorly soluble compounds are becoming ever more prevalent in the industry’s pipeline, and we have many customers who require formulation help to advance such problematic compounds,”​ explained Egerton.

He said Bend’s formulation expertise provides a “reliable, rapid and efficient drug formulation platform."

Ray agreed that Quotient’s “RapidFACT provides our clients with a game-changing advantage in advancing their compounds."

The deal marks the latest stage in Quotient Clinical’s development, which began in 2009 with parent company, Quotient Bioresearch’s acquisition of Charles River Laboratories’ early-stage clinical research facility in Edinburgh, Scotland.

It is also the second collaboration Bend has formed in as many months following a deal with US contract research organisation (CRO), PPD in October.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers